Literature DB >> 2920506

Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis.

T K Henthorn1, J Benitez, M J Avram, C Martinez, A Llerena, J Cobaleda, T C Krejcie, R D Gibbons.   

Abstract

From a sample of 149 unrelated Spaniards, individuals were phenotyped for their ability to hydroxylate debrisoquin and O-demethylate dextromethorphan. The distribution of urinary metabolic ratios for each test was analyzed by univariate gaussian mixture distributions analysis to determine the number of populations, the mean and standard deviation of the metabolic ratios for each population, and the proportion belonging to each population. For the 124 subjects phenotyped with both the debrisoquin and dextromethorphan tests a bivariate analysis was performed. The results demonstrate that both tests similarly separated this sample into two populations, with 10% belonging to poor metabolizer phenotypes. In addition, the correlation between the metabolic ratios from each test is significant, indicating that they are measuring the same biologic trait and the certainty of correctly identifying the debrisoquin oxidation phenotype of an individual is improved by using the results of both tests.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2920506     DOI: 10.1038/clpt.1989.36

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

Review 1.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

2.  CYP2D6 genotype and phenotype determination in a Mexican Mestizo population.

Authors:  Marisol López; Jorge Guerrero; Helgi Jung-Cook; María Elisa Alonso
Journal:  Eur J Clin Pharmacol       Date:  2005-10-26       Impact factor: 2.953

Review 3.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

4.  The rationale for case-control methodology in epidemiological studies of cancer risk (response to Speirs et al., 1990)

Authors:  N Caporaso; J R Idle
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

Review 5.  Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype.

Authors:  A Llerena; J Cobaleda; C Martínez; J Benítez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

6.  Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population.

Authors:  Waheed Adeola Adedeji; Sharon Iyobor Igbinoba; Titilayo O Fakeye; Ibrahim Adebayo Oladosu; Fatai Adewale Fehintola; Qing Ma; Gene D Morse
Journal:  Expert Rev Clin Pharmacol       Date:  2017-08-30       Impact factor: 5.045

7.  On mixtures of three normal populations caused by monogenic inheritance: application to desipramine metabolism.

Authors:  K J Miescke; M N Musa
Journal:  J Psychiatry Neurosci       Date:  1994-07       Impact factor: 6.186

8.  Oxidative polymorphism of dextromethorphan in a Burundi population.

Authors:  F Nsabiyumva; Y Furet; E Autret; A P Jonville; M Breteau
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Oxidative polymorphism of debrisoquine is not related to human colo-rectal cancer.

Authors:  J M Ladero; J Benítez; J F González; E Vargas; M Díaz-Rubio
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism.

Authors:  R J Guttendorf; M Britto; R A Blouin; T S Foster; W John; K A Pittman; P J Wedlund
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.